Drug Database
AS

AS0-3B (AS03B1 / AS03B)

✓ Approved

GSK · 治疗药物

什么是 AS0-3B?

AS0-3B 是一种治疗药物,由GSK研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名AS03B1, AS03B
公司GSK
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

AS0-3B 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedBMC bioinformatics2026-11-19

Protein language models for viral entry protein prediction: a multi-scale ESM2 benchmark.

Beltrán Jorge F JF, Belén Lisandra Herrera LH, Lugo Aloyma A, Jimenez Luis L

Viral entry proteins mediate host recognition and membrane fusion and are major targets for vaccines and antivirals. Identifying them directly from sequence data is important for characterizing emerging viruses, particularly when similarity to experimentally characterized proteins is limited. We evaluated whether frozen embeddings from the ESM2 protein language model family can support accurate binary classification of viral entry proteins. We benchmarked embeddings from three ESM2 models (650 M, 3B, and 15B parameters) with five supervised classifiers (SVM-RBF, Random Forest, XGBoost, LightGBM, and MLP) on a curated, non-redundant, balanced dataset of 1092 reviewed viral proteins from UniProt/Swiss-Prot. Sequences were clustered at 40% identity with CD-HIT and split into training (n = 873) and independent test (n = 219) sets. Performance improved monotonically with model scale. The best configuration, ESM2 15B with SVM-RBF, achieved 88.6% accuracy, MCC = 0.772, and ROC-AUC = 0.956 on the test set. ESM2 3B with SVM-RBF performed similarly (88.1% accuracy, MCC = 0.765, ROC-AUC = 0.953), indicating that most gains were captured by the intermediate-scale model. Classical descriptor baselines based on AAC, DPC, and PseAAC achieved lower independent test performance, with the best descriptor baseline reaching MCC = 0.537 and ROC-AUC = 0.846. In an exploratory taxid-disjoint evaluation of the ESM2 650 M plus SVM-RBF model, mean MCC and ROC-AUC were 0.734 and 0.929, respectively. We also implemented ViralEntryPred ( https://www.biochemintelli.com/viralentrypred/ ), a web application for rapid screening. Frozen ESM2 embeddings provide effective feature representations for viral entry protein prediction within a curated balanced benchmark. Larger models improved performance consistently, but with diminishing returns beyond the 3B scale, supporting intermediate-scale protein language models as a practical trade-off between accuracy and computational cost. Exploratory taxid-disjoint analysis suggested robustness to unseen taxids, but validation on completely unseen viral families remains future work.

PMID 43052708
阅读全文 →
PubMedCardio-oncology (London, England)2026-11-19

Cardiovascular effects of chemoradiotherapy in patients with lung cancer: an [18F]FDG PET-CT imaging study.

Khaing Phyo H PH, Williams Michelle C MC, Newby David E DE, Tavares Adriana A S AAS

Cardiovascular and pro-atherogenic side-effects of chemoradiotherapy for non-small cell lung cancer (NSCLC) remain a major concern given the growing burden of cancer therapy-related cardiovascular disease. Atherosclerotic plaque burden can be measured using calcium scoring while plaque activity can be assessed using [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET). To investigate the impact of chemoradiotherapy on aortic atherosclerotic burden and disease activity in patients with advanced NSCLC undergoing repeated [18F]FDG PET and computed tomography (CT) scans. All [18F]FDG PET-CT scans of patients with stage 3B NSCLC from the American College of Radiology Imaging Network (ACRIN 6668) trial were retrieved from the Cancer Imaging Archive. Volumes of interest for the aorta, left ventricle and major non-cardiac organs were manually delineated. Calcium scores, mean standard uptake values (SUVmean) and target-to-background ratios (TBRmean) were quantified, and comparisons before and after treatment scans performed. Twenty-six patients (mean 60 ± 9 years, body-mass index 25 ± 5 kg/m2) met the inclusion criteria, with 23 having aortic atherosclerosis as evidenced by the presence of aortic calcification. Pre- and post-treatment scans were performed approximately 14 weeks apart. After chemoradiotherapy, aortic calcium score increased by 10% in calcified plaques (p < 0.05) and aortic [18F]FDG TBRmean uptake increased by 4% (p = 0.02). There were no changes in [18F]FDG uptake in other organs. Chemoradiotherapy has adverse effects on the vasculature, possibly through increased inflammation resulting in accelerated atherosclerotic disease. This increased cardiovascular risk in lung cancer survivors highlight the need for aggressive risk factor modification at the earliest opportunity.

PMID 43053135
阅读全文 →
PubMedArchives of biochemistry and biophysics2026-11-18

Unraveling the Inhibitory Potential of Hydrazone Derivatives Against Cholinesterases: Molecular Interactions, Kinetic Behavior and Structural Features.

Hussain Ishtiaq I, Ali Akbar A, Khan Shoaib S, Iqbal Tayyiaba T et al.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with impaired cholinergic neurotransmission. Inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) represents an established approach to its symptomatic management. In this study, five pyridine-based Schiff base derivatives (3a-3e) were synthesized through the condensation of 2-((6-chloropyridin-2-yl)oxy)acetohydrazide with substituted aromatic aldehydes, affording the target compounds in 84-90% yields. Their structures were characterized using spectroscopic techniques, and their in vitro cholinesterase inhibitory activities were evaluated using galantamine as the reference inhibitor. Compound 3b exhibited the greatest inhibitory activity within the series against both AChE and BuChE, with IC50 values of 48.75 and 32.50 μM, respectively, although galantamine showed greater potency (40.30 and 28.88 mM, respectively). Molecular docking was subsequently performed to explore the potential binding orientations and interactions of the synthesized compounds with the selected cholinesterase targets. Overall, the experimental findings identify 3b as the most active derivative within this series, while the docking results provide complementary computational insights. Further experimental validation, including confirmation of inhibitory potency, enzyme kinetics, and cellular toxicity, is required to establish its biological potential. These findings provide a preliminary basis for further investigation of pyridine-based hydrazone derivatives as cholinesterase inhibitors.

PMID 43051571
阅读全文 →
PubMedBritish journal of haematology2026-11-17

Complex karyotype and non-BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia.

Mashima Kiyomi K, Fernandes Stacey M SM, Mikhaleva Mariia M, Azevedo Roberta Santos RS et al.

We retrospectively analysed 646 chronic lymphocytic leukaemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) at Dana-Farber Cancer Institute from 2014 to 2023. Among them, 122 underwent next-generation sequencing (NGS) during or at the next office visit after BTKi therapy (ibrutinib [IBR], 85; acalabrutinib [ACA], 23; pirtobrutinib [PIR], 9; vecabrutinib [VEC], 1; zanubrutinib [ZANU], 4). Compared with the non-progressor (NP) group (N = 75), patients with NGS at progression (PD group, N = 47) more commonly had 17p deletion, complex karyotype, heavier prior treatment exposure and prior exposure to a different BTKi before the current regimen. We found 321 mutations in 67 genes, with more mutations in the PD group (231 mutations), including 39 BTK (BTK C481S/F/R/Y, L528W and T474I/L) and 26 phospholipase C gamma 2 (PLCG2) mutations. Among the 12 PD patients with serial samples, all acquired new or expanded BTK or TP53 mutations. Complex karyotype, specifically 8p loss, was significantly enriched in the PD group. tumour protein p53 (TP53), splicing factor 3b subunit 1 (SF3B1), protein phosphatase, Mg2 +/Mn2 + dependent 1D (PPM1D) and notch receptor 2 (NOTCH2) mutations were also significantly more prevalent in the PD group (all p < 0.05). Additionally, pathogenic mitogen-activated protein kinase (MAPK) pathway mutations trended more common and had higher variant allele frequencies (VAFs) in the PD group (p = 0.047). These findings suggest that TP53 aberration and 8p-loss-associated complex karyotype, as well as several non-BTK driver mutations, are enriched in BTKi-resistant patients.

PMID 43041018
阅读全文 →
PubMedAJOG global reports2026-11-16

Maternal and neonatal outcomes of Kielland's rotational forceps-assisted vaginal births in a tertiary care center.

Naseef Paul P, Leps Caroline C, Almoi Elham E, Kane Daniel D et al.

Rates of second-stage Cesarean section (CS) have increased substantially, contributing to higher maternal morbidity and long-term risks in future pregnancies, including repeat CS and placenta accreta spectrum. Reducing unnecessary second-stage CS is therefore an important goal in modern obstetric care. Fetal malposition, particularly occiput transverse and posterior positions, is a key cause of labor dystocia and operative delivery. While several interventions exist, their success is variable. Kielland's rotational forceps can facilitate vaginal birth and potentially avoid CS, but their use has declined due to safety concerns and limited training, leaving a gap in contemporary evidence comparing outcomes with other delivery methods. To compare maternal and neonatal outcomes between rotational and nonrotational forceps use in a tertiary care setting. A retrospective cohort study was conducted of all forceps-assisted births at a tertiary care hospital in Toronto, between January 2014 and December 2021. Maternal outcomes included postpartum hemorrhage defined as estimated blood loss of 500 mL or more, and significant obstetric anal sphincter injuries defined as 3B, 3C and fourth degree perineal lacerations. Neonatal outcomes included Apgar scores, cord blood gases, need for resuscitation, and neonatal head trauma. Among 1606 forceps-assisted births, 26 (1.6%) required Kielland's rotational forceps. Episiotomy was universal in the rotational group (n=26/26, 100%) compared with 90.1% (n=1423/1580) in the nonrotational group. Significant OASIS occurred less frequently with rotational forceps (7.6%, n=2/26 vs 10.8%, n=172/1580), while rates of PPH were comparable (26.9%, n=7/26 vs 28.8%, n=456/1580). No major PPH (≥1000 mL) or shoulder dystocia occurred in the rotational group. Low 1-minute Apgar scores (<7) were more common in the rotational group (26.9%, n=7/26 vs 14%, n=227/1580), but all infants achieved scores ≥7 at 5 minutes. No cases of cephalohematoma, subgaleal hematoma, or intracranial hemorrhage occurred in the rotational group. Kielland's rotational forceps are a safe alternative to second-stage CS when performed by experienced operators. Their use was not associated with excess major maternal morbidity or significant neonatal trauma, in comparison to nonrotational forceps. Our data support efforts to transfer these skills to trainees and larger studies are needed to confirm these single institution findings.

PMID 43036802
阅读全文 →
PubMedDiabetologia2026-11-15

Triphasic decline in kidney function after islet transplantation: sex-based differences and the impact of calcineurin inhibitor immunosuppression in a 20 year single-centre cohort.

Carr Alice L J ALJ, Marfil-Garza Braulio A BA, Ling Ying Y, Oram Richard A RA et al.

Islet transplantation alone (ITA) is an established treatment for severe hypoglycaemia in type 1 diabetes, requiring calcineurin inhibitor-based immunosuppression, which is associated with nephrotoxicity. These limitations have driven longstanding interest in calcineurin inhibitor-free strategies, which are now entering clinical translation. The aim of this study was to evaluate long-term kidney function in 223 adults (41% male) undergoing ITA at the University of Alberta Hospital (1999-2018) using eGFR. Mixed-effects models were used to assess eGFR decline rates (ml min-1 1.73 m-2 per year) stratified by sex and baseline eGFR. Acute eGFR changes were assessed within 3 months of each infusion. Univariate and multivariable Cox models and competing risk regression were used to identify factors associated with progression to stage 3b chronic kidney disease (CKD) or worse (eGFR <45 ml min-1 1.73 m-2) in individuals with baseline eGFR ≥45 ml min-1 1.73 m-2. eGFR declined rapidly in the first year post-transplant (-11.52 ml min-1 1.73 m-2 per year; 95% CI -13.92, -9.00), then stabilised, with decline rates of -3.12 (95% CI -3.84, -2.28) and -1.08 (95% CI -1.80, -0.36) ml min-1 1.73 m-2 per year at 1-5 and 5-20 years, respectively. Female recipients experienced a greater first-year decline than male recipients (-14.79 ml min-1 1.73 m-2 per year [95% CI -17.92, -11.66] vs -6.75 ml min-1 1.73 m-2 per year [95% CI -10.49, -3.01]; p=0.0012). Individuals with baseline eGFR <60 ml min-1 1.73 m-2 had a similar first-year decline compared to those with preserved function (-3.99 ml min-1 1.73 m-2 per year [95% CI -13.31, 5.33] vs -12.03 ml min-1 1.73 m-2 per year [95% CI -14.57, -9.49]; p=0.10). Progression to stage 3b CKD occurred in 21% of participants (47/222) over a median of 6.4 years. Female sex (sub-distribution HR 2.17; 95% CI 1.15, 4.17; p=0.017) and lower baseline eGFR (sub-distribution HR 0.96 per ml min-1 1.73 m-2; 95% CI 0.94, 0.98; p=0.0009) were independent predictors of progression. Although calcineurin inhibitor-based immunosuppression induces rapid early eGFR decline, its progression slows substantially beyond 5 years. Female sex and lower pre-transplant eGFR independently predicted CKD progression. This sex disparity remains to be fully understood, as male and female recipients did not differ in baseline eGFR or tacrolimus exposure. These findings establish a long-term renal safety benchmark within the largest and longest-running ITA programme, and identify subgroups who are most likely to benefit from emerging calcineurin inhibitor-free strategies.

PMID 43034240
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多AS0-3B